Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug takes on leading cause of blindness in the elderly

NCT ID NCT06722157

Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called BI 771716 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 202 adults aged 50 and older will receive either the new drug or an existing treatment (pegcetacoplan) as eye injections. The goal is to see if BI 771716 can slow the growth of damaged areas in the eye better than the current standard of care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

202 people

The number who actually took part.

Started

Jan 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age at least 50 years old at the time of randomization visit * Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial * Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use are provided in the participant information. Male participants must be ready and able to use either a condom or abstinence as contraceptive measures * Diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), where the total GA lesion area must be ≥2.5 square millimetres (mm²) and ≤17.5 mm² as measured by Fundus autofluorescence (FAF) * If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥1.25 mm² * Note: Fellow eye is not required to have GA * Note: subfoveal GA lesions (defined as GA lesions within 1 micron of the foveal center point) will be allowed to be enrolled until a maximum of approximately 60% of participants with subfoveal GA lesions are enrolled. Participants with subfoveal GA lesions already in screening at the time the cap has been reached may be considered for randomization. * Fellow eye must have sufficient visual function compared to the study eye, per the investigator's medical judgment in consultation with the patient, to support the patient's daily functioning * BCVA letter score of ≥24 letters, using the ETDRS chart in the study eye (equivalent to ≥20/320 on the Snellen chart). Note: If both eyes meet eligibility criteria, the eye with the worse visual function per the investigator's medical judgment in consultation with the patient, will be selected as the study eye. If both eyes have similar visual function, the study eye will be selected per the investigator's medical judgment in consultation with the patient * further inclusion criteria apply Exclusion criteria * GA lesions whose area cannot be accurately defined in the study eye * Exudative neovascular AMD (eAMD) in the study eye \-- Note: eAMD in the fellow eye is allowed. However, if the fellow eye is to be considered for microperimetry and other analyses (as defined in the trial statistical analysis plan), then eAMD is not allowed in either eye. * Previously received treatment in the study eye for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer * Previously received an investigational medication (oral or intravitreal) for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer * Currently enrolled in another investigational device or drug trial, or 30 days or 5 half-lives, whichever is longer since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Any previous use of gene therapy or cell therapy is not permitted * Additional eye disease as follows: * Any eye disease in the study eye that could compromise BCVA * Uncontrolled glaucoma or ocular hypertension with intraocular pressure \>24 millimetre of mercury (mmHg) in study eye * History of high myopia \>8 diopters in the study eye * Anterior segment and vitreous abnormalities that would preclude adequate observation with spectral domain optical coherence tomography in the study eye * Ocular conditions at the discretion of the investigator that might interfere with outcome of the trial in the study eye * Active intraocular inflammation in the study eye * Active infectious conjunctivitis in either eye * Prior vitrectomy surgery in the study eye * History of major intraocular surgeries including major corneal surgery. Uneventful cataract surgery, refractive surgery, oculoplastic surgery, strabismus surgery, and other extraocular surgery may be permitted if they have occurred more than 3 months prior to baseline in the study eye * further exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy Macular degeneration, age related

Contacts and locations

Locations

  • Associated Retina Consultants

    Gilbert, Arizona, 85297, United States

  • Associated Retina Consultants, Ltd.

    Phoenix, Arizona, 85020, United States

  • Austin Clinical Research, LLC

    Austin, Texas, 78750, United States

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California, 94598, United States

  • Butchertown Clinical Trials

    Louisville, Kentucky, 40206, United States

  • Charleston Neuroscience Institute - Charleston

    Charleston, South Carolina, 29414, United States

  • Colorado Retina Associates

    Lakewood, Colorado, 80228, United States

  • Connecticut Eye Consultants, PC

    Danbury, Connecticut, 06810, United States

  • Envision Ocular, LLC

    Bloomfield, New Jersey, 07003, United States

  • Eye Associates of New Mexico

    Albuquerque, New Mexico, 87109, United States

  • Eye Associates of Pinellas

    Pinellas Park, Florida, 33782, United States

  • Eye Research Foundation

    Newport Beach, California, 92663, United States

  • Global Research Management

    Glendale, California, 91204, United States

  • Illinois Retina Associates - Oak Park

    Oak Park, Illinois, 60304, United States

  • Long Island Vitreoretinal Consultants - Westbury

    Westbury, New York, 11590, United States

  • Mid Atlantic Retina - Bethlehem

    Bethlehem, Pennsylvania, 18017, United States

  • Mid Atlantic Retina Specialists

    Hagerstown, Maryland, 21740, United States

  • Mississippi Retina Associates

    Madison, Mississippi, 39110, United States

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114, United States

  • Phoenix Retina Associates

    Phoenix, Arizona, 85050, United States

  • Piedmont Eye Center

    Lynchburg, Virginia, 24502, United States

  • Rand Eye Institute

    Deerfield Beach, Florida, 33064, United States

  • Red River Research Partners, LLC

    Plano, Texas, 75024, United States

  • Retina Associates of Southern California

    Huntington Beach, California, 92647, United States

  • Retina Associates of Utah

    Salt Lake City, Utah, 84107, United States

  • Retina Consultants of Minnesota

    Edina, Minnesota, 55435, United States

  • Retina Consultants of San Diego

    Poway, California, 92064, United States

  • Retina Consultants of Texas - Katy

    Katy, Texas, 77494, United States

  • Retina Consultants of Texas - Schertz

    Schertz, Texas, 78154, United States

  • Retina Consultants of Texas-Beaumont-70319

    Beaumont, Texas, 77707, United States

  • Retina Consultants of Texas-Bellaire-67493

    Bellaire, Texas, 77401, United States

  • Retina Consultants of Texas-The Woodlands-67575

    The Woodlands, Texas, 77384, United States

  • Retina Foundation of the Southwest

    Dallas, Texas, 75231, United States

  • Retina Group of Florida

    Fort Lauderdale, Florida, 33308, United States

  • Retina Group of New England, PC

    Waterford, Connecticut, 06385, United States

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona, 85255, United States

  • Retina Vitreous Associates of Florida

    St. Petersburg, Florida, 33711, United States

  • Retinal Consultants Medical Group

    Sacramento, California, 95825, United States

  • Retinal Consultants Medical Group, Inc

    Modesto, California, 95356, United States

  • Retinal Consultants of San Antonio

    San Antonio, Texas, 78240, United States

  • Southeast Retina Center, PC

    Augusta, Georgia, 30909, United States

  • Spokane Eye Clinic

    Spokane, Washington, 99204, United States

  • Tennessee Retina

    Nashville, Tennessee, 37203, United States

  • University Retina and Macula Associates

    Lemont, Illinois, 60439, United States

  • University of Missouri Health System

    Columbia, Missouri, 65212, United States

  • Verum Research, LLC

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.